Vimta Labs (524394) investor relations material

Executive summary

• FY 2026 delivered strong execution and double-digit growth in revenue, EBITDA, and PAT, with consistent leadership in pharmaceutical research and food testing, and significant overseas revenue contributions.

• Entry into biologics contract research and development services marks a strategic milestone, with FY 2027 focused on execution and credibility in this new vertical.

• Talent retention in scientific and leadership roles remains strong, supporting ongoing quality and innovation.

• Board approved the incorporation of a wholly owned subsidiary in the USA and reappointment of Executive Chairman for five years.

• Continued investment in infrastructure and capacity expansion to support future growth.

Financial highlights

• Q4 FY 2026 total income was INR 1,120 million, up 16.6% year-on-year; EBITDA margin at 37.6%.

• FY 2026 total income was INR 4,163 million, up 19.5% year-on-year; EBITDA margin at 35.8%.

• FY 2026 PAT was INR 775 million, up 16.1% year-on-year; basic EPS for the year was INR 17.4.

• Cash and cash equivalents at INR 650.6 million as of March 31, 2026; net debt-free balance sheet.

• Cash flow from operating activities for FY 2026 was INR 1,471.42 million, up from INR 940.54 million year-over-year.

Outlook and guidance

• Management targets maintaining growth momentum, aiming for INR 5,000 million annualized revenue, with optimism for FY 2027 despite external uncertainties.

• Biologics vertical expected to build traction in FY 2027, with significant revenue contribution anticipated in later years.

• Focus on capacity expansions, operational excellence, and penetration into new markets, with emphasis on service innovation and technology adoption.

• Dividend of INR 2 per share recommended for FY 2025-26, with record date set for June 18, 2026.